Database for understanding cachexia in colon cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a prospective clinico-biological database focused on cachexia and undernutrition in patients with colon cancer. It seeks to enhance knowledge about the relationship between colon cancer and cachexia, which is a severe syndrome characterized by significant weight loss and metabolic changes. By collecting biological samples and clinical data, the study intends to optimize therapeutic management and improve patient outcomes. The research will also explore the impact of nutritional approaches on the well-being and survival of these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old,
2. Patient treated at the Montpellier Regional Cancer Institute for colon cancer not eligible for surgery (of the primary tumor or associated metastases), whether undergoing treatment or not,
3. Patient requiring treatment for colon cancer (chemotherapy, targeted therapy, etc.),
4. Patient having accepted the constraints of the research and the blood samples planned for the research
5. Patient affiliated to Social Protection system
6. Informed consent form signed

Exclusion Criteria:

1. Patient requiring surgery (for treatment of colon cancer or metastasis)
2. Patient with exclusive peritoneal carcinomatosis
3. Patient requiring radiotherapy
4. Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
5. Pregnant and/ or breastfeeding women
6. Patient cared for an emergency context

Where it's running

• Institut Régional du cancer de Montpellier
  Montpellier, France Recruiting

Study contacts

• Study coordinator: Jean-Pierre Bleuse, MD
• Email: DRCI-icm105@icm.unicancer.fr
• Phone: 4 67 61 31 02

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.